Now Available for Public Comment: Notice of Proposed Rulemaking (NPRM) for FDAAA 801 and NIH Draft Reporting Policy for NIH-Funded Trials

Neoadjuvant Doxorubicin, Polyglutamate Paclitaxel, Capecitabine and Metronomic Chemotherapy in Breast Cancer

This study has been withdrawn prior to enrollment.
(Sponsor withdrew due to funding issues)
Sponsor:
Collaborator:
CTI BioPharma
Information provided by:
University of Southern California
ClinicalTrials.gov Identifier:
NCT01227408
First received: January 8, 2009
Last updated: May 19, 2014
Last verified: May 2014
No Study Results Posted on ClinicalTrials.gov for this Study
Study was withdrawn before participants were enrolled.
  Study Status: This study has been withdrawn prior to enrollment.
  Estimated Study Completion Date: No date given
  Primary Completion Date: February 2009 (Final data collection date for primary outcome measure)